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Abstract: Retinoic acid is one of the most well-known agents able to induce differentiation in several
types of tumours. Unfortunately, most of the tumours are refractive to the differentiation cues.
The aim of this investigation was to analyse the effects of prolonged treatment with retinoic acid on
two cell lines of neural origin refractive to differentiation. Cells were also treated with retinoic acid
in combination with a poly(ADP-ribosyl) polymerase (PARP) inhibitor because PARP1 is a known
chromatin modulator and can influence the process of differentiation. The main methods comprised
tumour cell line culturing and treatment; analysis of RNA and protein expression after cell treatment;
as well as analysis of urokinase activity, migration, and proliferation. Both cell lines continued to
proliferate under the prolonged treatment and showed increase in urokinase plasminogen activator
activity. Analysis of gene expression and cell phenotype revealed different mechanisms, which only
in neuroblastoma H4 cells could indicate the process of epithelial-mesenchymal transition. The data
collected indicate that the activity of the urokinase plasminogen activator, although belonging to
an extracellular protease, does not necessary lead to epithelial-mesenchymal reprogramming and
increase in cell migration but can have different outcomes depending on the intracellular milieu.
Keywords: neuroglioblastoma cell line; glioblastoma; retinoic acid; PARP1; urokinase;
epithelial-mesenchymal transition
1. Introduction
Among many hallmarks of cancer, the prevailing group of features is considering the inability
of tumour cells to stop proliferating, either through avoiding senescence, differentiation, cell cycle
arrest, or programmed cell death [1]. Although different chemotherapeutics aim to induce tumour
cell death, there are also possibilities to cure tumours by induction of the differentiation process,
which diminishes the cell’s ability to proliferate. While the treatment of some forms of promyelocytic
leukaemia by derivates of retinoic acid is a standard therapy causing cell differentiation, other types of
tumours and leukaemia are mostly refractive to differentiation [2–4]. The most common differentiation
agent is retinoic acid (RA; all-trans retinoic acid, ATRA), a compound derived from the vitamin A [5].
In the canonical pathway, RA binds to retinoic acid receptors (RAR) and retinoid X receptors (RXR)
in the nucleus, which belong to the steroid-thyroid superfamily. The receptors then bind to specific
DNA sequences on the target promoters and recruit the transcription machinery [5]. The receptors
without bound ligands act as transcription repressors in a complex with chromatin modifiers. RAR was
also been found to be able to bind to peroxisome proliferator-activated receptors (PPAR) if certain
adaptor molecules are present in the cell and, in this way, can regulate another set of genes [6]. RA can
act as a morphogen, and its most known target genes are HOX genes [7]. Therefore, it is involved
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in complex processes of vertebrate neurogenesis, neural stem cell differentiation, and development
of several specific types of neurons [5,8]. Pathways involved in RA-mediated embryonic stem cell
differentiation toward neuronal tissue involve interactions with different pathways, including Notch,
Wnt, MAP kinases, Src kinases, inhibition of GSKβ, and others [7,8].
In this work, we combined the retinoic acid treatment with poly(ADP-ribosyl)polymerase (PARP)
inhibition. PARP1 is an enzyme involved in the process of poly(ADP-ribosyl)ation, the addition
of polyADP-ribose chains on certain proteins in order to change the chromatin structure and to
facilitate the process of DNA damage repair. PARP1 can modify some transcription factors and
consequently participate in stem cell establishment and the differentiation process. Due to its influence
on the chromatin structure and transcription, we investigated whether it could contribute to retinoic
acid-induced cellular processes [9].
In this article, we analysed the changes in two tumour cell lines of neural origin after treatment
with retinoic acid and a PARP inhibitor for a prolonged time period. The treated cells continued
to proliferate and increased urokinase activity. As this extracellular protease is involved in tissue
remodelling and could be involved in epithelial-mesenchymal transition [10–12], we analysed the
cellular features and the expression of a set of genes involved in these processes.
2. Materials and Methods
2.1. Cell Culture and Growth Assessment
Glioblastoma (A1235) and neuroglioblastoma (H4) cells were cultured in Dulbecco’s Modified
Eagle Medium (DMEM, Sigma-Aldrich, Taufkirchen, Germany) supplemented with 10% foetal bovine
serum (Sigma–Aldrich) at 37 ◦C and 5% CO2. A1235 cells were a kind gift from S. A. Aaronson
(National Cancer Institute, Bethesda, MD, USA) [13]. Neuroblastoma H4 cells were commercially
available at ATCC (Manassas, VA, USA). The cells were tested for the presence of mycoplasma with
the EZ-PCR Mycoplasma Test Kit (Biological Industry, Beit-Haemek, Israel).
Cells were treated with ATRA (all-trans retinoic acid) (Sigma-Aldrich) and PJ-34, a PARP inhibitor
(Sigma-Aldrich). Control cells were treated with DMSO (Sigma-Aldrich). For prolonged treatment,
cells were treated with 10 µM ATRA and 20 µM PJ-34 every second day and reseeded if needed.
The 10-µM ATRA treatment for 5–10 days is considered the standard condition for neuroblastoma cell
differentiation [14], and 20 µM PJ-34 was shown to be effective in PARP inhibition [15].
Cell growth was assessed by crystal violet staining. Cells were seeded on a 96-well plate in
multiplicate, and every day, one set of cells was fixed with cold methanol. At the end of the assay,
the plate was stained with crystal violet and, after dissolving in 1% sodium dodecyl sulphate (SDS),
absorbance was measured on 595 nm by a microplate reader [16].
2.2. Analysis of Enzymatic Activity
Urokinase-type plasminogen activator (uPA) activity was assayed by radial caseinolysis of the
conditioned media as described previously [17]. Samples were measured in duplicates and in two
biological replicas and compared with the standard uPA (Leo Pharmaceutical Products, Ballerup,
Denmark) curve. Experiments were repeated at least two times.
Metalloproteinase activity was examined in the conditioned media by zymography on the
polyacrylamide gel copolymerized with gelatine, according to protocol [18].
2.3. RNA Preparation, cDNA Synthesis, and Quantitative Real-Time PCR
Total RNA was extracted from cells using TRI Reagent (Sigma), and cDNA was synthesized from 2
µg of total RNA by Primescript RTase (Takara, Kusatsu, Japan) according to manufacturer’s instructions.
Quantitative real-time PCR (qRT-PCR) was performed using GoTaq® qPCR Master Mix (Promega,
Madison, WI, USA) in a 7500 Fast Real-Time PCR system (Applied Biosystems, ThermoFisher Scientific,
Waltham, MA, USA). Gene expression was validated by comparison with HPRT gene expression.
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Primer sequences, designed by IDT PrimerQuest software package (Integrated DNA Technologies,
Inc., Coralville, IA, USA) used for PCR reactions, are listed in Supplementary Table S1. Some of the
primer sequences, such as those for HPRT, HES1, c-MYC, TGFβ, SMAD4, SMAD7, SNAIL1, SNAIL2,
TWIST1, ZEB1, and PARG were used previously [19,20].
2.4. SDS PAGE and Western Blot
Total cell extracts were prepared using lysis buffer containing a cocktail of protease inhibitors
(Carl Roth, Karlshuhe, Germany), as described previously [21]. Protein expression was analysed by
Western blot [21]. The primary antibodies used were PAI1 (Becton Dickenson, Franklin Lakes, NJ, USA),
uPA (Cusabio Technology LCC, Houston, TX, USA), and β-actin (Santa Cruz, Dallas, Texas, USA).
Densitometric analysis was performed using the ImageJ program (version 1.52a, National Institute of
Health, Bethesda, MD, USA).
2.5. Migration Assays
Migration assay was performed in Transwell chambers, according to methods reported
previously [22]. Two to 4 × 104 cells were seeded in DMEM with or without added ATRA and
PJ-34, in a Transwell cell culture chamber with the 8-µm pore size (BRAND, Wertheim, Germany).
Cells were allowed to migrate for 18 to 24 h toward DMEM supplemented with 10% serum, with or
without added ATRA or PJ-34.
2.6. Statistical Analysis
Data were statistically analysed using the software package Microsoft Office and GraphPad Prism
5 (Graph Pad Software. Inc, San Diego, CA, USA). The test used for comparison of the results between
the control and the treated cells was one-way ANOVA with Tukey posttest. Significance was set at
p-value < 0.05.
3. Results
3.1. The Effect of ATRA and PARP Inhibition on Neuroglioblastoma Cell Growth and Morphology
To investigate whether PARP1 inhibition could influence the cells’ ability to differentiate after
ATRA treatment, two tumour cell lines of neural origin, glioblastoma A1235 and neuroglioblastoma
H4, were treated with ATRA in combination with a PARP inhibitor, PJ-34. We monitored the cell
proliferation under treatment for several days. Both cell lines continued to proliferate at nearly a control
rate, except for a little slowing down in growth of A1235 and H4 cells after 4 days of treatment with
ATRA and the PARP inhibitor (Figure 1).
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Figure 1. Growth curves of A1235 and H4 cells treated with all-trans retinoic acid (ATRA) and the
poly(ADP-ribosyl) polymerase (PARP) inhibitor: Cells were treated ev ry second ay with 10 µM ATRA
and 20 µM PJ-34 and their combination. Cell proliferati n was determin d by crystal vio et staining
and absorbance measurement. (A) A1235 cells; (B) H4 cells. * Th mean values were significantly
different from the control (p < 0.05).
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A1235 cells have a fibroblast-like morphology, which showed phenotypic changes during the
experiment. Cells treated with ATRA adopted a more epithelial-like shape (Figure 2A). H4 cells have
epithelioid morphology, and we did not observe significant changes during the treatment period
(Figure 2B).
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Figure 2. Morphology of A1235 glioblastoma and H4 neuroglioblastoma cells after 9 days of treatment
with ATRA and the PARP inhibitor: Microphotographs were taken with epifluorescent microscope
Axiovert 40 CFL. (A) A1235 cells; (B) H4 cells; a: control; b: cells treated with 20 µM PJ-34; c: cells
treated with 10 µM ATRA; and d: cells treated with 10 µM ATRA and 20 µM PJ-34. Pictures were taken
at magnification of 100×, scale bar = 100 µm.
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3.2. The Effect of ATRA and PARP Inhibition on Urokinase Activity
Our previous experiments showed that A1235 cells had the ability to increase the activity of
urokinase plasminogen activator (uPA) when treated with certain drugs [23,24]. We hypothesized
that these cells possibly began the process of epithelial-mesenchymal transition, with changes in the
uPA activity as a sign of reprogramming. These experiments led us to test the uPA activity after
treatment with ATRA and the PARP inhibitor after one day and after prolonged treatment of up to two
weeks. The uPA activity was determined in the serum-free conditioned media by radial caseinolysis.
The results revealed that A1235 cells increased the uPA activity several times after ATRA treatment:
uPA induction was detected already after one day, as well as after prolonged treatment (Figure 3A,B).
When cells grown in ATRA and PJ-34 medium for a longer period were left without a treatment for
a week, uPA activity returned to a basal level.
The same experiment was also performed with H4 neuroglioblastoma cells. After one day of
treatment, there were only small differences in the uPA activity between the cells treated with ATRA,
PJ-34, and their combination and the control, untreated cells (Figure 3C). After more than 9 days of
treatment, the uPA activity was increased in cells treated with ATRA. PARP inhibition did not influence
this feature (Figure 3D).
Biomedicines 2019, 7, x FOR PEER REVIEW 5 of 16 
PJ-34; c: cells treated with 10 µM ATRA; and d: cells treated with 10 µM ATRA and 20 µM PJ-34. 
Pictures were take  at magnification f 100×, scale bar = 100 µm. 
3.2. The Effect of ATRA and PARP Inhibition on Urokinase Activity 
Our previous experiments showed that A1235 cells had the ability to increase the activity of 
urokinase plasminogen activator (uPA) when treated with certain drugs [23,24]. We hypothesized 
that these cells possibly began the process of epithelial-mesenchymal transition, with changes in the 
uPA activity as a sign of reprogramming. These experiments led us to test the uPA activity after 
treatment with ATRA and the PARP inhibitor after one day and after prolonged treatment of up to 
two weeks. The uPA activity was determined in the serum-free conditioned media by radial 
caseinolysis. The results revealed that A1235 cells increased the uPA activity several times after 
ATRA treatment: uPA induction was detected already after one day, as well as after prolonged 
treatment (Figure 3A,B). When cells grown in ATRA and PJ-34 medium for a longer period were left 
without a treatment for a week, uPA activity returned to a basal level. 
The same experiment was also performed with H4 neuroglioblastoma cells. After one day of 
treatment, there were only small differences in the uPA activity between the cells treated with 
ATRA, PJ-34, and he r comb ation and the control, untreated cells (Figure 3C). After m re than 9 
days of treatment, the uPA activity was increased in cells treated with ATRA. PARP inhibition did 
not influence this feature (Figure 3D). 
 
Figure 3. uPA activity of A1235 and cells H4 after treatment with ATRA and the PARP inhibitor: 
Cells were treated with 10 µM ATRA and 20 µM PJ-34 and their combination every second day. After 
first day and after more than 9 days of treatment, cells were incubated for 6 h in medium without 
serum and the urokinase activity was determined in conditioned medium by caseinolysis. The uPA 
activity was estimated according to the calibration curve of human uPA and protein concentration of 
corresponding lysates and presented in proportion to control cell values. (A) A1235 cells treated for 1 
day; (B) A1235 cells treated for prolonged time period; (C) H4 cells treated for 1 day; and (D) H4 cells 
treated for prolonged time period. S: 1-day treatment; L: prolonged treatment; PJ-34: cells treated 
with PARP inhibitor; ATRA: cells treated with ATRA; ATRA + PJ-34: cells treated with ATRA and 
PARP inhibitor. * The mean values were significantly different from the control (p < 0.05). 
Experiments were done two times, and representative results are shown. 
3.3. The Effect of ATRA and PARP Inhibition on EMT Gene Expression 
Figure 3. uPA activity of A1235 and cells H4 after treatment with ATRA and the PARP inhibitor: Cells
were treated with 10 µM ATRA and 20 µM PJ-34 and their combination every second day. After first
day and after more than 9 days of treatment, cells were incubated for 6 h in medium without serum and
the urokinase activity was determined in conditioned medium by caseinolysis. The uPA activity was
estimated according to the calibration curve of human uPA and protein concentration of corresponding
lysates and presented in proportion to control cell values. (A) A1235 cells treated for 1 day; (B) A1235
cells treated for prolonged time eriod; (C) H4 cells treated for 1 day; and (D) H4 cells treated for
prolonged time period. S: 1-day treatment; L: prolonged treatment; PJ-34: cells treated wi h PARP
inhibitor; TRA: cells treated with ATRA; ATRA + PJ-34: cells treated with ATRA and PARP inhibitor.
* The mean values were significantly different from the control (p < 0.05). Experime s were done two
times, and repres ntative resul s are shown.
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3.3. The Effect of ATRA and PARP Inhibition on EMT Gene Expression
The uPA system is considered to be involved in EMT, as it can be regulated by mesenchymal
master transcription factors [12]. To better understand the processes going on in the cells treated with
ATRA, we analysed the expression of several groups of genes in both cell types after treatment with
ATRA and the PARP inhibitor. First, we analysed the expression of a set of genes involved in the uPA
activity regulation: uPA, its inhibitors PAI1 and PAI2, and membrane uPA receptor uPAR.
In the glioblastoma cells, ATRA increased uPA expression after one and 9 days. The expression of
its inhibitor PAI1 was also increased after prolonged treatment, while that of PAI2 was on the very
low level. uPAR expression showed small changes in the treated cells only after prolonged treatment
(Figure 4A,B).
To see whether changes in the uPA system could be linked to the changes in expression of the
EMT master transcription factors, we tested TWIST, SNAIL1, SNAIL2, and ZEB1 [10–12]. After one day
of treatment with ATRA, a decrease in ZEB1, TWIST, and SNAIL2 mRNA was observed, and after 9
days, significant SNAIL2 and TWIST inhibition persisted.
The third group of genes, of which the expression was tested in A1235 cells, were downstream
effectors of EMT or its upstream triggers, such as genes involved in the formation of the extracellular
matrix (ECM) or cell adhesion [10,11]. N-CADHERIN and INTEGRIN subunits showed a decrease
in expression as a consequence of the prolonged ATRA and PJ-34 treatment. As a TGFβ system can
be an initiator of the changes in the EMT, we analysed its expression as well as the expression of
downstream SMAD4 and SMAD7, with the latter involved in its negative feedback regulation [11].
In A1235 cells, although TGFβ showed small downregulation after ATRA treatment, these changes
were not reflected on SMAD4 and SMAD7 expression after prolonged treatment. PARP inhibition did
not influence TGFβ expression. Considering the Notch pathway, its downstream target HES1 was
upregulated by ATRA. We also analysed the expression of c-MYC, which showed downregulation
after treatment with both ATRA and PJ-34. PARG1, an enzyme which cleaves polyADP chains [9],
was decreased in dependence on PARP inhibition.
We also analysed the expression of the same group of genes in H4 neuroblastoma cells treated under
the same conditions. Significant changes were observed in the uPA and PAI expression. uPA expression
was increased after 9 days of ATRA treatment, and PAI1 was decreased. PAI2 expression showed
an increase only after 24 h of treatment with the PARP inhibitor, and uPAR expression was not
significantly changed (Figure 4C,D).
Regarding the expression of the master transcription factors, the expression of TWIST and SNAIL2
was decreased after ATRA treatment. PARP inhibition alleviated ATRA effects on the expression of
certain target genes, some master transcription factors, and their downstream targets (Supplementary
Table S2). Considering integrins, only INTEGRIN β3 showed an increase in ATRA and PJ-34 treated cells.
After 9 days, the expression of most of the INTEGRIN subunits was on the control level. Analysis of
TGFβ system expression revealed changes in TGFβ and SMAD7 expression. After 9 days of treatment,
TGFβ expression showed an increase in samples where the PARP inhibitor was added, while SMAD7
was decreased in ATRA-treated cells. HES1 and PARG1 expression was also changed in ATRA-treated
cells (Figure 4C,D).
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and H4 cells after 1 and 9 days of ATRA and PJ-34 treat ent: Cells were treated with 10 µM ATRA
and 20 µM PJ-34 and their combination every second da . as isolated from cells treated for 1
and 9 days, and cDNA was produced and examined by . Relative gene expression level was
obtained by normalizati n of its values with those of hypoxanthine-guanine p osphoribosyltr sf rase
(HPRT) and is presented as a fold change in comparison with untreated control cell values. (A) A1235
cells treated for 1 day; (B) A1235 cells treated for 9 days; (C) H4 cells treated for 1 day; and (D) H4 cells
treated for 9 days. S: 1-day treatment; L: prolonged treatment; PJ-34: cells treated with PARP inhibitor;
ATRA: cells treated with ATRA; ATRA + PJ-34: cells treated with ATRA and the PARP inhibitor.
Data are expressed as mean ± SD. * The mean values were significantly different from the control
(p < 0.05). Experiments with prolonged cell treatment were done at least two times, and representative
results are shown.
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3.4. The Effect of ATRA and PARP Inhibition on the Plasminogen Activation System Proteins
The uPA system was also analysed on the protein level. Proteins were isolated from the cells
treated for a prolonged time with ATRA and the PARP inhibitor. In A1235 cells, although a small
increase in uPA could be observed in some treated cells, there was also an increase in PAI1 in all
treated samples (Figure 5A,C). In H4 cells, increase in uPA was detected in cells treated with ATRA in
combination with the PARP inhibitor and decrease in PAI1 was detected in all treated cells (Figure 5B,D).
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Figure 5. Western blot analysis of uP and P I-1 in A1235 and H4 cells after treatment with ATRA
and PJ-34: After the prolonged tr t t ith 10 µM ATRA and 20 µM PJ-34 and their combination,
the whole c ll lysates were immun against indicated antibodies. (A) Analysis of A1235 cells;
(B) analysis of H4 cells; (C,D) densitometric analysis of western bl t films of A1235 and H4
cells, respectively. PJ-34: cells treated with PARP inhibitor; ATRA: cells treated with ATRA; ATRA
+ PJ-34: cells treated with ATRA and the PARP inhibitor. Data are expressed as mean ± SD. * The
mean values were significantly different from the control (p < 0.05). Experiments were done two times,
and representative results are presented.
3.5. The Effect of ATRA and PARP Inhibition on Cell Migration and Matrix Metalloprotease Expression
In order to examine the effect of urokinase activity and EMT master transcription factor expression
on the ability of cells to migrate, we performed cell migration analysis. Cells were seeded in Transwells
and exposed to the PARP inhibitor and/or ATRA for ~20 h. After one day of treatment, migration of
both A1235 and H4 cells, control and treated, was similar (Figure 6A,C). After prolonged treatment,
we observed a decrease in A1235 and an increase in H4 migration after treatment with ATRA
(Figure 6B,D).
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Figure 6. Analysis of cell migration after ATRA and PJ-34 treat ent: Cells were see ed in Transwell
chambers and allowed to migrate oward the mediu ru in the pr sence or in the absence
of ATRA or PJ-34. Membranes were stained with cryst t, and the absorbance was measured
spectro hotometrically. (A) A1235 cells’ migration after 1 day of treatment; (B) A1235 cells’ migration
after prolonged treatment; (C) H4 cells’ migration after 1 day of treatment; and (D) H4 cells’ migration
after prolonged treatment. S: 1-day treatment; L: prolonged treatment; PJ-34: cells treated with 20 µM
PJ-34; ATRA: cells treated with 10 µM ATRA; ATRA + PJ-34: cells treated with 20 µM PJ-34 and 10 µM
ATRA inhibitor. * The mean values were significantly different from the control (p < 0.05). Experiments
were done two times.
As matrix metalloproteases (MMP) are often involved in the process of migration and are
expressed in mesenchy al cells, we also analysed their expression and activity in both cell lines
after th prolonged treatment with ATRA and the PARP inhibit r. As s veral met lloprot ases act as
gelatinases, their ac ivity was examined by zymography on a gelatine-containing gel [25]. Gelat ases
detected in A1235 cells had very weak activity. In H4 cells, there was an increase in gelatinase activity
in media obtained from samples treated with ATRA alone and in combination with PJ-34 (Figure 7A
and Figure S1). As the technique applied can detect several MMPs, we analysed the expression of
MMP2, MMP3, and MMP9 on the RNA level by qPCR. In A1235 cells, only MMP2 and MMP9 were
detected and a decrease in MMP2 expression was observed. In H4 cells, only MMP2 and MMP3
were expressed and MMP3 expression was increased after ATRA treatment in combination with PJ-34
(Figure 7B,C).
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tumours prone to differentiation is very low, due probably to active signalling pathways forcing 
cells on proliferation and dominating over differentiations cues [4,26,27]. Ostensive proliferation 
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Figure 7. Metalloprotease activity and expression in A1235 and H4 cells after ATRA and PJ-34 treatment:
(A) Zymography of H4 cells. After the prolonged treatment with 10 µM ATRA and 20 µM PJ-34 and
their co bination, conditioned H4 c ll wer collected, concentrated, and analysed by zymography on
a gelatine-containing polyacrylamide gel. (B) qPCR analysis of MMP expression in A1235 cells; (C)
qPCR analysis of MMP expression in H4 cells. RNA was isolated from cells after prolonged treatment,
cDNA was produced and examined by qRT-PCR. Relative gene expression level was obtained by
normalization of its values with those of hypoxanthine-guanine phosphoribosyltransferase (HPRT)
and is presented as a fold change in comparison with untreated control cell values. PJ-34: cells treated
with 20 µM PJ-34; ATRA: cells treated with 10 µM ATRA; ATRA + PJ-34: cells treated with 20 µM
PJ-34 and 10 µM ATRA inhibitor; MMP2: metalloproteinase 2; MMP3: metalloproteinase 3; MMP9:
metalloproteinase 9. * The mean values were significantly different from the control (p < 0.05).
4. Discussion
ATRA is often used as a differentiation agent in certain types of tumour cells and could be
considered a targeted ch motherap utic, with optimal effects. Unfortunately, the number of tumours
prone to differentiation is very low, due probably to active signalling pathways forcing cells on
proliferation and dominating over differentiations cues [4,26,27]. Ostensive proliferation after ATRA
and PARP inhibitor treatment in the neuroblastoma and glioblastoma cell lines investigated indicated
insensitivity to drug treatment and cells’ inability to differentiate. Also, there were no neurite outgrowth
and significant morphological changes indicating differentiation. Despite this, ATRA did cause
changes in intracellular signalling, indicating cellular reprogramming. We first detected an increase
in the urokinase activity after RA treatment. Urokinase plasminogen activator is an extracellular
enzyme often considered to influence cell migration and invasion and was found to be involved in
epithelial-mesenchymal transition (EMT) [12,28]. In this process, by obtaining mesenchymal features,
epithelial cells (or cells of other types in the similar process) acquire the ability to migrate, to produce
extracellular matrix proteins and proteases, to change their integrin and receptor expression, and to
loosen tight and adhesive junctions with neighbouring cells. This reprogramming is a normal process
during development but also present in wound healing and other physiological processes [10,11,29].
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Nowadays, it comes into the focus of investigation because of its role in tumour spreading and tumour
stem cell biology [30–32]. Thus, we analysed a set of cellular features involved in this process.
RA treatment increased urokinase activity in both cell lines of neural origin, but the pattern of
induction was not the same. In H4 neuroblastoma cells, we observed minimal changes after 1 day
of treatment but the activity significantly increased after prolonged treatment. These changes were
reversible, and activity decreased after culturing the cells without the drug. In these cells, increase in
urokinase activity could be ascribed to coordinated increase in uPA and decrease in PAI1 expression.
In parallel, there was also an increase in metalloprotease activity as well as in cell migration. On the
other hand, there were no changes in the epithelial phenotype of H4 cells. Expression of several
genes regulating cell attachment, such as INTEGRINS, FIBRONECTIN, and N-CADHERIN, was only
sporadically changed, i.e., N-CADHERIN was increased only in cells treated with ATRA alone. EMT
master transcription factors TWIST and SNAIL2 were downregulated by RA [10,31]. Analysis of TGFβ
signalling in the RA-treated cells showed a decrease in SMAD7 expression, its negative regulator.
TGFβ expression, on the contrary, showed increase in cells treated with the PARP inhibitor. The PARP
inhibitor’s influence on ATRA-dependent expression could be seen in several TGFβ-dependent genes,
such as N-CADHERIN, INTEGRIN, and TWIST [11]. It is known that PARP can regulate physiological
responses to TGFβ by PARPylation of the activated Smad proteins. This modification was found to
increase Smad complex dissociation from DNA and to decrease gene response to TGFβ signalling and
epithelial-mesenchymal transition dependent on it [33,34]. Thus, PARP inhibition could change the
duration of TGFβ signals and interfere with signalling induced by ATRA. However, the final outcome
seemed to be dependent on the intracellular milieu which determines downstream TGFβ targets and
general TGFβ response. Complex relations between TGFβ-induced EMT and PARP activity were
also confirmed recently in mammary epithelial cells, which showed inhibition of EMT under PARP
inhibition [35]. Therefore, although uPA, PAI1, and PAI2 are TGFβ-responsive genes and final changes
in the uPA activity and other EMT-like features in H4 cells correlated only with ATRA treatment,
H4 cells did not exhibit all of the EMT-like features but it could be ascribed to partial EMT or similar
process found in both physiological processes and in tumour biology [29,36].
c-MYC expression often correlates with cell proliferation ability, and in H4 cells, it was
not significantly decreased after prolonged treatment. Duffy et al. [27] analysed neuroblastoma
cells with N-MYC overexpression during ATRA treatment and concluded that N-Myc regulated
differentiation-relevant genes in the opposite way in comparison with ATRA. They found N-Myc-related
inhibition of TGFβ signalling and interactions of their networks on multiple levels. The authors
concluded that N-Myc expression dominated over other signalling pathways and disabled
differentiation network activation by ATRA. Chen et al. [37] found that the defective regulation
of c-MYC or its upstream signalling in breast tumours leads to c-MYC unresponsiveness to TGFβ
signals. H4 cells could have similar mechanisms of differentiation avoidance, possibly not dependent
directly on c-MYC but on proliferation signalling cooperating with Myc, such as Akt pathways [38].
The A1235 glioblastoma cell line shared with H4 cells the ability to avoid differentiation and to
continue to proliferate under RA treatment, as well as to increase urokinase activity. However, in these
cells, the urokinase activity showed different dynamics; it showed immediate upregulation which
remained on the high level during treatment. As in H4 cells, the activity was downregulated after RA
removal. Increase in the urokinase activity was accompanied by the upregulation in uPA expression
and also by the upregulation of its inhibitor PAI1. PAI2 expression was low, so we could suppose that it
did not influence significantly the uPA activity. On the protein level, there was no significant increase in
the uPA expression correlating with activity. On the contrary, increase in PAI1 expression was detected
in the cell lysates. A1235 cells were described previously to increase the urokinase activity when treated
with chemotherapeutics, but it was shown that ZEB1 could be involved in coordinated increases in uPA
and decreases in PAI1 expression [12]. RA regulated urokinase activity differently. Our hypotheses
are that extracellular uPA activity could be regulated on the level of uPA or PAI1 secretion or by the
differential expression of some other specific inhibitors, which were found recently [39–42].
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Despite the increase in the urokinase activity, a number of changes observed in RA-treated A1235
cells indicated the absence of EMT-like reprogramming. Cells showed the decrease in migration ability,
low expression of metalloproteases, and epithelioid-like morphology. Also, there was a decrease in
TWIST and SNAIL2 expression, as well as in those of integrins and N-CADHERIN. The TGFβ system
in A1235 cells correlated with ATRA treatment, causing the downregulation of TGFβ expression.
ATRA treatment was found to cause the reversal of EMT in several experimental systems.
Cui et al. [43] analysed its effects on hepatocellular carcinoma cells and found the suppression of
proliferation, migration, and invasion, as well as downregulation of the mesenchymal genes TWIST,
SNAIL, N-CADHERIN, and VIMENTIN. Zanetti et al. [44] also found that ATRA induces epithelial
differentiation program in breast tumour cells. ATRA was also found to increase the amounts of
VE-cadherin, β-catenin, as well as cell-to-cell contacts and to decrease the cell migration. SNAIL1 was
decreased when ATRA was applied in combination with EGF. In addition, it was found that ATRA
activated the TGFβ pathway which possibly did a functional switch to antimigratory behaviour.
We could conclude that both ATRA-dependent pathways and PARP inhibition induce changes
in cell-specific signalling network, dependent on the intracellular milieu. Although both cell lines of
neural origin increased the activity of urokinase after ATRA treatment, H4 cells showed also some of
the hallmarks of EMT, while glioblastoma A1235 cells showed signs of the opposite process.
5. Conclusions
Glioblastoma A1235 and neuroglioblastoma H4 cells were resistant to the induction of
differentiation by ATRA and PARP inhibition. Both cell lines increased uPA activity after ATRA
treatment, but the regulation of uPA system elements as well as changes in gene expression network
were cell-type specific. While ATRA induced changes resembling the hallmarks of EMT in one cell line,
in the other, it caused the features of the opposite process. PARP inhibition did not have a consistent
effect by itself or in addition to ATRA. The data indicate that the activity of urokinase plasminogen
activator, although an extracellular protease, does not necessarily lead to epithelial-mesenchymal
reprogramming but could have different outcomes dependent on the intracellular milieu.
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